Author:
de Gooijer Cornedine J.,Borm Frank J.,Scherpereel Arnaud,Baas Paul
Reference42 articles.
1. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial;Alley;Lancet Oncol.,2017
2. OA08.03 phase II trial of pembrolizumab (NCT02399371) in previously-treated malignant mesothelioma (MM): final analysis;Desai;J Thoracic Oncol,2018
3. Pembrolizumab as palliative immunotherapy in malignant pleural mesothelioma;Metaxas;J Thoracic Oncol,2018
4. Clinical efficacy and safety of nivolumab: results of a multicenter, open-label, single-arm, Japanese phase 2 study in malignant pleural mesothelioma (MERIT);Okada;Clin Cancer Res.,2019
5. Programmed death 1 blockade with nivolumab in patients with recurrent malignant pleural mesothelioma;Quispel-Janssen;J Thoracic Oncol,2018
Cited by
64 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献